...
首页> 外文期刊>Clinical and applied thrombosis/hemostasis >Relative neutralization of the biological actions of sulfaminoheparosans (k5 derivatives) and heparins by protamine sulfate.
【24h】

Relative neutralization of the biological actions of sulfaminoheparosans (k5 derivatives) and heparins by protamine sulfate.

机译:硫酸鱼精蛋白相对中和磺胺肝素聚糖(k5衍生物)和肝素的生物作用。

获取原文
获取原文并翻译 | 示例

摘要

Biosynthetic, semisynthetic, and synthetic analogues of heparins are currently developed as substitute antithrombotic agents for heparin. Sulfaminoheparosan (SAH) represents a bacterial polysaccharide (K5)-derived antithrombotic polymer from which pharmacologically active products with varying molecular weights (5-25 kDa) can be derived. These agents have been shown to exhibit pharmacologic effects comparable to heparins. The objective of this investigation is to determine the relative neutralization profile of various SAH derivatives, also called as bioheparins, by protamine sulfate. Four SAH fractions with varying molecular weights (20, 9, 7, and 6 kDa), a low molecular weight heparin (LMWH), tinzaparin, and unfractionated heparin (UFH) were supplemented to normal human pool plasma over a concentration range of 6.2 to 100 mug/mL. A fixed amount of protamine sulfate at 25 mug/mL (final concentration) was supplemented to determine the neutralization profile by performing tests such as prothrombin time (PT), activated partial thromboplastin time (APTT), Heptest, prothrombin-induced clotting time (PiCT), and amidolytic anti-Xa and anti-IIa assays. Protamine sulfate produced varying degrees of neutralization of all bioheparin fractions in the clotting assays. In the amidolytic anti-IIa assay relatively stronger inhibition was noted for all agents than inhibition of FXa. On a cumulative basis the neutralization profile of SAHs was comparable with heparins. These results suggest that the anticoagulant activities of SAH derivatives can be antagonized by protamine sulfate. These studies warrant further in vivo investigation to validate the relative neutralization profile of sulfaminoheparosans.
机译:肝素的生物合成,半合成和合成类似物目前被开发为肝素的替代抗血栓形成剂。磺胺肝素(SAH)代表一种细菌多糖(K5)衍生的抗血栓形成聚合物,可从中衍生出具有不同分子量(5-25 kDa)的药理活性产物。这些药物已显示出与肝素相当的药理作用。这项研究的目的是确定硫酸鱼精蛋白对各种SAH衍生物(也称为生物肝素)的相对中和谱。在6.2至90的浓度范围内,将四种具有不同分子量(20、9、7和6 kDa),低分子量肝素(LMWH),替扎肝素和普通肝素(UFH)的SAH馏分补充到正常人血浆中100杯/毫升。通过执行诸如凝血酶原时间(PT),活化的部分凝血活酶时间(APTT),Heptest,凝血酶原诱导的凝血时间(PiCT)等测试,补充固定量的25杯/毫升(最终浓度)的硫酸鱼精蛋白以确定中和曲线。 ),以及酰胺化抗Xa和抗IIa分析。在凝结分析中,硫酸鱼精蛋白对所有生物肝素组分产生不同程度的中和作用。在酰胺化抗IIa分析中,与FXa抑制相比,所有试剂均具有相对较强的抑制作用。累积地,SAH的中和作用与肝素相当。这些结果表明,硫酸鱼精蛋白可以拮抗SAH衍生物的抗凝活性。这些研究需要进行进一步的体内研究,以验证磺胺肝素的相对中和谱。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号